Abstracts Archive - Page 761 of 2607 - ACR Meeting Abstracts

Abstract Number: 0838 • ACR Convergence 2021
Predictors of Treatment for Inflammatory Arthritis with Immune Modulating Medications (IMM) in US Veterans
Tawnie Braaten¹, shaobo Pei², Anitha Rathod², Gopi Penmetsa³, Kevin Douglas⁴, Jodi Walker⁴, Jerry Clewell⁵ and Jessica Walsh⁶, ¹Salt Lake City Veteran Affairs and University of Utah Medical Center, Salt Lake City, UT, ²University of Utah, Salt Lake City, UT, ³Salt Lake City Veteran Affairs and University of Utah Medical Centers, Salt Lake City, UT, ⁴AbbVie Inc., North Chicago, IL, ⁵Abbvie Inc, North Chicago, IL, ⁶Salt Lake City Veteran Affairs Medical Center (VAMC)/University of Utah Hospital, Salt Lake City, UT
Background/Purpose: Non-treatment and treatment delays contribute to suboptimal symptom control and irreversible joint damage in patients with inflammatory arthritis (IA). This investigations objective was to…
Abstract Number: 0839 • ACR Convergence 2021
Comparative Treatment Effectiveness in Rheumatoid Arthritis with and Without Concomitant Sjögren’s Syndrome – Results from the Swiss Clinical Quality Management Cohort
Lisa Christ¹, Seraphina Kissling², Ruediger B. Mueller³, Axel Finckh⁴, Benjamin Fisher⁵, Britta Maurer¹, Burkhard Moeller⁶ and Florian Kollert¹, ¹Department of Rheumatology and Immunology, University Hospital (Inselspital) and University of Bern, Bern, Switzerland, ²Statistics and Data Management Group, Swiss Clinical Quality Management Foundation, Zurich, Switzerland, ³Clinic of Rheumatology, Medical University Hospital Aarau, Aarau, Switzerland, ⁴University Hospital of Geneva, Geneve - Vesenaz, Switzerland, ⁵Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham; National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre and Department of Rheumatology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom, ⁶Inselspital - University Hospital Bern, Bern, Switzerland
Background/Purpose: The variety of treatment options in RA contrasts with a lack of personalized medicine. The presence of concomitant SjS might be associated with differerences…
Abstract Number: 0840 • ACR Convergence 2021
Modelling of Disease Activity in Patients with Inflammatory Arthropathies Treated with Etanercept Originator or Biosimilar as First-Line Biologic: A Real-World Observational Study Using the OPAL Dataset
Claire Deakin¹, Geoffrey Littlejohn², Hedley Griffiths³, Tegan Smith⁴, Catherine OSullivan⁵ and Paul Bird⁶, ¹OPAL Rheumatology Ltd, Sydney, Australia, ²Monash University, Melbourne, Australia, ³Barwon Rheumatology Service, Geelong, Australia, ⁴OPAL Rheumatology Ltd, Kogarah, Australia, ⁵OPAL Rheumatology Ltd, Queenscliff, Australia, ⁶University of New South Wales, Sydney, Australia
Background/Purpose: The availability of biosimilars as non-proprietary versions of established biologic disease-modifying anti-rheumatic drugs (bDMARDs) has increased around the world. Since April 2017 both the…
Abstract Number: 0841 • ACR Convergence 2021
Persistence on JAK Inhibitors in Daily Practice: Evaluation of the Rhadar-registry
Linus Risser¹, Torsten Witte², Peter Bartz-Bazzanella³, Cay Von der Decken⁴, Johannes Knitza⁵, Sándor P. Fekete⁶, Alexander Zink⁷, Georg Gauler⁸, Patrick Wurth⁹, Peer Aries¹⁰, Kirsten Karberg¹¹, Christoph Kuhn¹², Florian Schuch¹³, Susanna Späthling-Mestekemper¹⁴, Wolfgang Vorbrüggen¹⁵, Mathias Englbrecht¹⁶, Martin Welcker¹⁷ and Stefan Kleinert¹⁸, ¹Medizinische Hochschule Hannover, Hannover, Germany, ²Hannover Medical School, Hannover, Germany, ³Rhein-Maas Klinikum, Wuerselen, Germany, ⁴Klinik für Internistische Rheumatologie, Rhein-Maas-Klinikum, Würselen, Germany, ⁵Department of Internal Medicine 3 Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nrnberg, University Hospital Erlangen, Erlangen, Germany, ⁶Department of Computer Science, TU Braunschweig, Braunschweig, Germany, ⁷Department of Dermatology and Allergy, School of Medicine, Technical University of Munich, Munich, Germany, ⁸rheumapraxis, Osnabrck, Germany, ⁹Rheumatologische Schwerpunktpraxis, Osnabrück, Germany, ¹⁰Rheumatologie in Hamburg, Hamburg, Germany, ¹¹Praxis für Rheumatologie und Innere Medizin, Berlin, Germany, Berlin, Germany, ¹²Praxis für Rheumatologie, Karlsruhe, Germany, Karlsruhe, Germany, ¹³Praxisgemeinschaft Rheumatologie-Nephrologie, Erlangen, Germany, ¹⁴Rheumapraxis München, München, Germany, ¹⁵Verein zur Förderung der Rheumatologie e.V., Würselen, Germany, ¹⁶Freelance Healthcare Data Scientist, Eckental, Germany., Eckental, Germany, ¹⁷MVZ für Rheumatologie, Planegg, Germany, ¹⁸Praxisgemeinschaft Rheumatologie - Nephrologie (PGRN), Erlangen, Germany
Background/Purpose: The treatment strategy for rheumatoid arthritis (RA) includes achieving remission or at least low disease activity within six months of starting therapy. Active RA…
Abstract Number: 0842 • ACR Convergence 2021
What Is the Success Rate in Clinical Trials of Discontinuation Glucocorticoids After Their Use as Bridging Therapy – a Systematic Literature Review
Lotte van Ouwerkerk¹, Isabell Nevins¹, Patrick Verschueren², Josef Smolen³, Robert Landewé⁴, Johannes Bijlsma⁵, Andreas Kerschbaumer³, Tom WJ Huizinga¹, Rene Westhovens⁶, Cornelia F. Allaart¹ and Sytske Anne Bergstra¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²University Hospitals Leuven - KULeuven, Leuven, Belgium, ³Medical University of Vienna, Vienna, Austria, ⁴Amsterdam Rheumatology & Clinical Immunology Center, Amsterdam, Netherlands; Zuyderland MC, Heerlen, Netherlands, ⁵Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁶University Hospitals KU Leuven, Maaseik, Belgium
Background/Purpose: Short-term glucocorticoid (GC) bridging therapy results in rapid suppression of disease activity during the initial treatment of rheumatoid arthritis (RA) patients with DMARDs. But…
Abstract Number: 0843 • ACR Convergence 2021
Prevalence and Trends of Infections in Hospitalized Patients with Rheumatoid Arthritis in the United States
Pushti Khandwala¹, Anila Hussain² and Devashish Desai¹, ¹Crozer Chester Medical Center, Glen Mills, PA, ²Crozer Chester Medical Center, Glen Mills
Background/Purpose: Rheumatoid arthritis (RA) patients have a higher risk of developing infections as compared to the patients without the diagnosis, and this risk is further…
Abstract Number: 0844 • ACR Convergence 2021
Switching Biologics and Failure to Attain Remission in the First Year Predicts bDMARD Refractory Disease in Rheumatoid Arthritis: A 15-year Follow up of the Alberta Biologics Pharmacovigilance Cohort
Stephanie Keeling¹, Britney Jones², Jill Hall³, Joanne Homik⁴, Anthony Russell¹, Luck Lukusa⁵, Sasha Bernatsky⁶ and Walter Maksymowych⁷, ¹Division of Rheumatology, University of Alberta, Edmonton, AB, Canada, ²University of Alberta/University of Calgary, Edmonton, AB, Canada, ³Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada, ⁴University of Alberta, Edmonton, AB, Canada, ⁵Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ⁶McGill University, Montréal, QC, Canada, ⁷Department of Medicine, University of Alberta, Alberta, Canada, Edmonton, AB, Canada
Background/Purpose: A subset of patients with rheumatoid arthritis (RA) experience refractory disease and do not attain remission imparting worse long-term outcomes. We evaluated RA patients…
Abstract Number: 0845 • ACR Convergence 2021
A Non-Interventional Prospective Observational Study of Treatment with Etanercept Biosimilar (SB4) in Rheumatoid Arthritis in Real Life Clinical Practice; Interim Analysis of the ‘BENEFICIAL’ Study
Panagiotis Athanassiou¹, Andreas Bounas², Dimitrios Boumpas³, Prodromos Sidiropoulos⁴, Christina Tsalapaki⁵, Alexandros Garyfallos⁶, Eleftheria Grika⁷, Paraskevi Voulgari⁸, Angeliki Kekki⁹, Zafeirios Anagnostopoulos⁹, Georgios Karachalios⁹ and Nikos Antonakopoulos⁹, ¹Department of Rheumatology, St. Paul’s Hospital of Thessaloniki, Thessaloniki, Greece, ²General Clinic of Patras “Olympion”, Rheumatology, Patras, Greece, ³“Attikon” University Hospital, Rheumatology and Clinical Immunology Unit ,4th University Pathology Clinic, Athens, Greece, ⁴Department of Rheumatology, Clinical Immunology and Allergy, University of Crete, Heraklion, Greece, ⁵General Hospital of Athens “Hippokratio", Department of Medicine, National and Kapodistrian University of Athens, Athens, Greece, Athens, Greece, ⁶General Hospital of Thessaloniki “Ippokratio" , Τhessaloniki, Greece, Thessaloniki, Greece, ⁷Rheumatology Clinic, General Hospital “Evangelismos”, Athens, Greece, ⁸Rheumatology Clinic, Department of Internal Medicine, Medical School, University of Ioannina, Ioannina, Greece, ⁹Genesis Pharma SA, Athens, Greece, Athens, Greece
Background/Purpose: SB4 is an etanercept biosimilar that obtained EU regulatory approval in 2016, and became available in Greece in 2018. Due to lack of published…
Abstract Number: 0846 • ACR Convergence 2021
Psychometric Evaluation and Measurement Invariance of English and French Versions of the UCLA Loneliness Scale in Systemic Sclerosis: A Scleroderma Patient-Centered Intervention Network Cohort Study
Chelsea Rapoport¹, Alyssa Choi², Linda Kwakkenbos³, Marie-Eve Carrier⁴, Karen Gottesman⁵, Scott Roesch⁶, Brett Thombs⁷ and Vanessa Malcarne⁶, ¹SDSU/UC San Diego Joint Doctoral Program in Clinical Psychology, La Jolla, CA, ²SDSU/UC San Diego Joint Doctoral Program in Clinical Psychology, San Diego, CA, ³Department of Clinical Psychology, Radboud University Behavioural Science Institute, Nijmegen, Netherlands, ⁴Lady Davis Institute for Medical Research, Jewish General Hospital, Montréal, QC, Canada, ⁵Scleroderma Foundation, Southern California Chapter, Danvers, MA, ⁶SDSU/UC San Diego Joint Doctoral Program in Clinical Psychology; Department of Psychology, San Diego State University, San Diego, CA, ⁷Lady Davis Institute for Medical Research, Jewish General Hospital; Department of Psychiatry, McGill University, Montréal, QC, Canada
Background/Purpose: Loneliness is a pervasive experience that has been associated with poorer health-related quality of life, and remains understudied in patients with systemic sclerosis (SSc).…
Abstract Number: 0847 • ACR Convergence 2021
A Psychometric Analysis of the Self-Efficacy for Managing Chronic Disease Scale in Systemic Sclerosis: A Scleroderma Patient-Centered Intervention Network Cohort Study
Alyssa Choi¹, Chelsea Rapoport², Linda Kwakkenbos³, Marie-Eve Carrier⁴, Karen Gottesman⁵, Scott Roesch⁶, Brett Thombs⁷ and Vanessa Malcarne⁶, ¹SDSU/UC San Diego Joint Doctoral Program in Clinical Psychology, San Diego, CA, ²SDSU/UC San Diego Joint Doctoral Program in Clinical Psychology, La Jolla, CA, ³Department of Clinical Psychology, Radboud University Behavioural Science Institute, Nijmegen, Netherlands, ⁴Lady Davis Institute for Medical Research, Jewish General Hospital, Montréal, QC, Canada, ⁵Scleroderma Foundation, Southern California Chapter, Danvers, MA, ⁶SDSU/UC San Diego Joint Doctoral Program in Clinical Psychology; Department of Psychology, San Diego State University, San Diego, CA, ⁷Lady Davis Institute for Medical Research, Jewish General Hospital; Department of Psychiatry, McGill University, Montréal, QC, Canada
Background/Purpose: Self-efficacy is a key determinant of health behaviors and the target mechanism of self-management programs for patients with chronic diseases. The Self-Efficacy for Managing…
Abstract Number: 0848 • ACR Convergence 2021
Automatic Hand Segmentation from Hand X-rays Using Minimized Training Samples and Machine Learning Models
Zilong Yang¹, Juan Shan², Carmine Guida², Jordan Blackadar¹, Tino Cheung¹, Jeffrey Driban³, Timothy McAlindon⁴ and Ming Zhang¹, ¹Wentworth Institute of Technology, Boston, MA, ²Pace University, New York, NY, ³Tufts Medical Center, Boston, MA, ⁴Tufts Medical Center, Arlington, MA
Background/Purpose: In many hand osteoarthritis (OA) studies (e.g., automatic Joint Space Width measuring), accurate hand segmentation is the first step towards making further analysis. However,…
Abstract Number: 0849 • ACR Convergence 2021
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Creating a Foundation for Linking Patient Reported Outcomes Measures with the International Classification of Functioning, Disability and Health
Hannah Bailey¹, Ananya Vasudevan¹, Emily Hickey², Aileen Ledingham³, Mary Slavin¹, Lewis Kazis⁴ and Ronald Tompkins⁵, ¹Boston University School of Public Health, Boston, MA, ²University of Wisconsin, Madison, WI, ³Boston University School of Public Health, Waltham, MA, ⁴Boston University, Spaulding Hospital and Harvard Medical School, Boston, MA, ⁵Harvard Medical School, Boston, MA
Background/Purpose: Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a devastating multi-system chronic disease, estimated to affect 1.5 million adults in the United States. The disease is…
Abstract Number: 0850 • ACR Convergence 2021
Regression Methods for Modeling Western Ontario and McMaster Universities Arthritis Index (WOMAC) Pain Scores for Early Stage Knee Osteoarthritis
Benjamin Sweigart and Michael LaValley, Boston University School of Public Health, Boston, MA
Background/Purpose: The Western Ontario and McMaster Universities Arthritis Index (WOMAC) pain score [range 0-20] is a common outcome measure for clinical trials and observational studies…
Abstract Number: 0851 • ACR Convergence 2021
Application of a Modified Recursive Feature Elimination Machine Learning Algorithm to Select Predictors of Mortality in Those with and Without Osteoarthritis
Siyeon Kim¹, Siqi Xiang¹, Liubov Arbeeva¹, Carolina Alvarez¹, Amanda Nelson¹, Yvonne Golightly¹, Leigh Callahan², Michael Kosorok¹ and Becki Cleveland³, ¹University of North Carolina at Chapel Hill, Chapel Hill, NC, ²University of North Carolina Thurston Arthritis Research Center, Chapel Hill, NC, ³Thurston Arthritis Research Center, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC
Background/Purpose: Radiographic osteoarthritis (rOA) and joint symptoms at the knee and hip are predictors of mortality. However, questions remain about the nature of the relationship…
Abstract Number: 0852 • ACR Convergence 2021
Bone Marrow Lesion Segmentation Using Synthetic Data and Deep Learning Models
Barak Michaely¹, Ming Zhang² and Juan Shan¹, ¹Pace University, New York, NY, ²Wentworth Institute of Technology, Boston, MA
Background/Purpose: Bone marrow lesions (BML) are indicators for knee osteoarthritis (OA) and can be detected from magnetic resonance imaging (MRI). Due to the small size,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].